Biosimilar Lymphocyte Modulator Global Market Report 2024

The biosimilar lymphocyte modulator market size has grown rapidly in recent years. It will grow from $1.71 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth observed in the historical period can be attributed to several key factors. These include the increasing incidence of immune-mediated diseases necessitating treatments involving lymphocyte modulators, a heightened awareness regarding the effectiveness of these medications among healthcare providers and patients, growing governmental support for the development and usage of biosimilars, and the expansion of the biosimilar market offering more options and accessibility. These elements collectively contributed to the growth and adoption of lymphocyte modulators in treating immune-related conditions during this period.

The biosimilar lymphocyte modulator market size is expected to see rapidly grown in the next few years. It will grow to $2.86 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. Anticipated growth in the upcoming period is driven by rising patient interest in biosimilars, an expanding patient demographic, increased demand for personalized medicine, a surge in requests for minimally invasive procedures, and the continual expansion of the biologic drug portfolio. Key trends forecasted include advancements in biosimilar technology, robust assurance of quality and efficacy, patient-focused approaches, and ongoing innovation in biosimilars and biologic medications.

Immunotherapy combined with various cancer treatments is anticipated to fuel growth within the biosimilar lymphocyte modulator market. Pairing immunotherapies with chemotherapy or radiation, for instance, enhances the efficacy of lymphocyte modulators. A study by researchers at Washington University School of Medicine in St. Louis in December 2021 showcased the benefits of pre-activated natural killer cells in a limited clinical trial for some adolescents and young adults with recurrent AML, augmenting the effectiveness of alternative chemotherapy. This combination approach not only enhances treatment effectiveness but also safeguards patients from life-threatening immune system reactions, thereby driving the market for lymphocyte modulators.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the biosimilar lymphocyte modulator market. These diseases involve the immune system erroneously targeting the body's own tissues and organs. Biosimilar lymphocyte modulators mitigate autoimmune diseases by modulating immune system activity, easing inflammation, and alleviating symptoms. An Imperial Biomedical Research Centre report in May 2023 highlighted that autoimmune disorders now affect roughly one in ten individuals, with 19 autoimmune diseases impacting about 10% of the population, showing higher prevalence among women (13%) than men (7%). Consequently, the surging incidence of autoimmune diseases propels the biosimilar lymphocyte modulator market. Tumor-infiltrating lymphocyte immunotherapy has gained significant traction due to its favorable outcomes in anti-cancer treatments. These lymphocytes occupy tumor tissues and have emerged as crucial biomarkers for predicting treatment efficacy, particularly in various solid tumors like breast cancer. In 2021, With promising results, companies like Lovance Biotherapeutics have initiated phase II trials of TIL therapy for solid tumor treatment, marking a significant development in this arena.

Key players in the biosimilar lymphocyte modulator market are introducing biosimilar versions of crucial drugs to stay competitive. Idacio (adalimumab-aacf), a TNF blocker and biosimilar to Humira (adalimumab), was launched by Fresenius Kabi AG in July 2023 for treating chronic autoimmune diseases in the U.S. Its availability in self-administered prefilled syringes and autoinjectors offers patients convenient dosing options for approved indications, marking a strategic move to enhance market presence and accessibility.

In November 2022, Biocon Biologics Ltd., an India-based biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. The acquisition brings Biocon Biologics closer to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and numerous emerging regions. In numerous emerging market positions, the merger of Viatris' acquired worldwide biosimilars company with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization Viatris Inc. Is a US-based pharmaceutical company that develops, licenses, manufactures, markets, and distributes generic and branded medicines.

Major companies operating in the biosimilar lymphocyte modulator market include Pfizer Inc., Biogen Inc., Celltrion Inc., Genentech Inc., Novartis AG, Sandoz International GmbH, Mylan N.V., Fresenius Kabi AG, Biocon Ltd., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., Lupin Limited, Stada Arzneimittel AG, Zydus Cadila, Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Alvotech, Coherus BioSciences, Innovent Biologics, Shanghai Henlius Biotech, BioXpress Therapeutics SA, Mabion SA, Polpharma Biologics, Prestige BioPharma, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical Group Co. Ltd., Wockhardt Ltd., Amega Biotech.

North America was the largest region in the biosimilar lymphocyte modulator market in 2023. Middle East is expected to be the fastest-growing region in the biosimilar lymphocyte modulator market report during the forecast period. The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Key types of drugs within the biosimilar lymphocyte modulator category include Campath-1H, natalizumab biosimilar, efalizumab (A1089-anti-CD11A biosimilar), daratumumab biosimilar (anti-CD38), and elotuzumab biosimilar (anti-CS1). For instance, Campath is a prescription medication primarily used to address symptoms associated with chronic lymphocytic leukemia (CLL) and can be administered alone or in combination with other drugs. These medications are utilized to treat a range of conditions such as arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, among others. In terms of distribution, they are typically available through online pharmacies and direct-to-consumer channels, ensuring accessibility to patients seeking these treatments.

The biosimilar lymphocyte modulator market research report is one of a series of new reports provides biosimilar lymphocyte modulator market statistics, including biosimilar lymphocyte modulator industry global market size, regional shares, competitors with a biosimilar lymphocyte modulator market share, detailed biosimilar lymphocyte modulator market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar lymphocyte modulator industry. This biosimilar lymphocyte modulator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilar lymphocyte modulator market consists of sales of roasted coffee, coffee concentrates, coffee extracts, flavorings, and syrups. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.